Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer (Q36504117)

From Wikidata
Jump to navigation Jump to search
scientific article published on 26 May 2009
edit
Language Label Description Also known as
English
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
scientific article published on 26 May 2009

    Statements

    Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer (English)
    Gerhardt Attard
    Alison H M Reid
    Christopher Parker
    Nikhil Babu Oommen
    Elizabeth Folkerd
    Christina Messiou
    Emilda Thompson
    David Dearnaley
    Johann S de Bono

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit